Cargando…
Development and Validation of a Chiral Liquid Chromatographic Assay for Enantiomeric Separation and Quantification of Verapamil in Rat Plasma: Stereoselective Pharmacokinetic Application
A novel, fast and sensitive enantioselective HPLC assay with a new core–shell isopropyl carbamate cyclofructan 6 (superficially porous particle, SPP) chiral column (LarihcShell-P, LSP) was developed and validated for the enantiomeric separation and quantification of verapamil (VER) in rat plasma. Th...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038655/ https://www.ncbi.nlm.nih.gov/pubmed/33917412 http://dx.doi.org/10.3390/molecules26072091 |
_version_ | 1783677425411948544 |
---|---|
author | Mohammed, Mostafa S. Hefnawy, Mohamed M. Al-Majed, Abdulrhman A. Alrabiah, Haitham K. Algrain, Nasser A. Obaidullah, Ahmad J. Altamimi, Abdulmalik S. Bin Jardan, Yousef A. Al-Hossaini, Abdullah M. |
author_facet | Mohammed, Mostafa S. Hefnawy, Mohamed M. Al-Majed, Abdulrhman A. Alrabiah, Haitham K. Algrain, Nasser A. Obaidullah, Ahmad J. Altamimi, Abdulmalik S. Bin Jardan, Yousef A. Al-Hossaini, Abdullah M. |
author_sort | Mohammed, Mostafa S. |
collection | PubMed |
description | A novel, fast and sensitive enantioselective HPLC assay with a new core–shell isopropyl carbamate cyclofructan 6 (superficially porous particle, SPP) chiral column (LarihcShell-P, LSP) was developed and validated for the enantiomeric separation and quantification of verapamil (VER) in rat plasma. The polar organic mobile phase composed of acetonitrile/methanol/trifluoroacetic acid/triethylamine (98:2:0.05: 0.025, v/v/v/v) and a flow rate of 0.5 mL/min was applied. Fluorescence detection set at excitation/emission wavelengths 280/313 nm was used and the whole analysis process was within 3.5 min, which is 10-fold lower than the previous reported HPLC methods in the literature. Propranolol was selected as the internal standard. The S-(−)- and R-(+)-VER enantiomers with the IS were extracted from rat plasma by utilizing Waters Oasis HLB C18 solid phase extraction cartridges without interference from endogenous compounds. The developed assay was validated following the US-FDA guidelines over the concentration range of 1–450 ng/mL (r(2) ≥ 0.997) for each enantiomer (plasma) and the lower limit of quantification was 1 ng/mL for both isomers. The intra- and inter-day precisions were not more than 11.6% and the recoveries of S-(−)- and R-(+)-VER at all quality control levels ranged from 92.3% to 98.2%. The developed approach was successfully applied to the stereoselective pharmacokinetic study of VER enantiomers after oral administration of 10 mg/kg racemic VER to Wistar rats. It was found that S-(−)-VER established higher C(max) and area under the concentration-time curve (AUC) values than the R-(+)-enantiomer. The newly developed approach is the first chiral HPLC for the enantiomeric separation and quantification of verapamil utilizing a core–shell isopropyl carbamate cyclofructan 6 chiral column in rat plasma within 3.5 min after solid phase extraction (SPE). |
format | Online Article Text |
id | pubmed-8038655 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80386552021-04-12 Development and Validation of a Chiral Liquid Chromatographic Assay for Enantiomeric Separation and Quantification of Verapamil in Rat Plasma: Stereoselective Pharmacokinetic Application Mohammed, Mostafa S. Hefnawy, Mohamed M. Al-Majed, Abdulrhman A. Alrabiah, Haitham K. Algrain, Nasser A. Obaidullah, Ahmad J. Altamimi, Abdulmalik S. Bin Jardan, Yousef A. Al-Hossaini, Abdullah M. Molecules Article A novel, fast and sensitive enantioselective HPLC assay with a new core–shell isopropyl carbamate cyclofructan 6 (superficially porous particle, SPP) chiral column (LarihcShell-P, LSP) was developed and validated for the enantiomeric separation and quantification of verapamil (VER) in rat plasma. The polar organic mobile phase composed of acetonitrile/methanol/trifluoroacetic acid/triethylamine (98:2:0.05: 0.025, v/v/v/v) and a flow rate of 0.5 mL/min was applied. Fluorescence detection set at excitation/emission wavelengths 280/313 nm was used and the whole analysis process was within 3.5 min, which is 10-fold lower than the previous reported HPLC methods in the literature. Propranolol was selected as the internal standard. The S-(−)- and R-(+)-VER enantiomers with the IS were extracted from rat plasma by utilizing Waters Oasis HLB C18 solid phase extraction cartridges without interference from endogenous compounds. The developed assay was validated following the US-FDA guidelines over the concentration range of 1–450 ng/mL (r(2) ≥ 0.997) for each enantiomer (plasma) and the lower limit of quantification was 1 ng/mL for both isomers. The intra- and inter-day precisions were not more than 11.6% and the recoveries of S-(−)- and R-(+)-VER at all quality control levels ranged from 92.3% to 98.2%. The developed approach was successfully applied to the stereoselective pharmacokinetic study of VER enantiomers after oral administration of 10 mg/kg racemic VER to Wistar rats. It was found that S-(−)-VER established higher C(max) and area under the concentration-time curve (AUC) values than the R-(+)-enantiomer. The newly developed approach is the first chiral HPLC for the enantiomeric separation and quantification of verapamil utilizing a core–shell isopropyl carbamate cyclofructan 6 chiral column in rat plasma within 3.5 min after solid phase extraction (SPE). MDPI 2021-04-06 /pmc/articles/PMC8038655/ /pubmed/33917412 http://dx.doi.org/10.3390/molecules26072091 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mohammed, Mostafa S. Hefnawy, Mohamed M. Al-Majed, Abdulrhman A. Alrabiah, Haitham K. Algrain, Nasser A. Obaidullah, Ahmad J. Altamimi, Abdulmalik S. Bin Jardan, Yousef A. Al-Hossaini, Abdullah M. Development and Validation of a Chiral Liquid Chromatographic Assay for Enantiomeric Separation and Quantification of Verapamil in Rat Plasma: Stereoselective Pharmacokinetic Application |
title | Development and Validation of a Chiral Liquid Chromatographic Assay for Enantiomeric Separation and Quantification of Verapamil in Rat Plasma: Stereoselective Pharmacokinetic Application |
title_full | Development and Validation of a Chiral Liquid Chromatographic Assay for Enantiomeric Separation and Quantification of Verapamil in Rat Plasma: Stereoselective Pharmacokinetic Application |
title_fullStr | Development and Validation of a Chiral Liquid Chromatographic Assay for Enantiomeric Separation and Quantification of Verapamil in Rat Plasma: Stereoselective Pharmacokinetic Application |
title_full_unstemmed | Development and Validation of a Chiral Liquid Chromatographic Assay for Enantiomeric Separation and Quantification of Verapamil in Rat Plasma: Stereoselective Pharmacokinetic Application |
title_short | Development and Validation of a Chiral Liquid Chromatographic Assay for Enantiomeric Separation and Quantification of Verapamil in Rat Plasma: Stereoselective Pharmacokinetic Application |
title_sort | development and validation of a chiral liquid chromatographic assay for enantiomeric separation and quantification of verapamil in rat plasma: stereoselective pharmacokinetic application |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038655/ https://www.ncbi.nlm.nih.gov/pubmed/33917412 http://dx.doi.org/10.3390/molecules26072091 |
work_keys_str_mv | AT mohammedmostafas developmentandvalidationofachiralliquidchromatographicassayforenantiomericseparationandquantificationofverapamilinratplasmastereoselectivepharmacokineticapplication AT hefnawymohamedm developmentandvalidationofachiralliquidchromatographicassayforenantiomericseparationandquantificationofverapamilinratplasmastereoselectivepharmacokineticapplication AT almajedabdulrhmana developmentandvalidationofachiralliquidchromatographicassayforenantiomericseparationandquantificationofverapamilinratplasmastereoselectivepharmacokineticapplication AT alrabiahhaithamk developmentandvalidationofachiralliquidchromatographicassayforenantiomericseparationandquantificationofverapamilinratplasmastereoselectivepharmacokineticapplication AT algrainnassera developmentandvalidationofachiralliquidchromatographicassayforenantiomericseparationandquantificationofverapamilinratplasmastereoselectivepharmacokineticapplication AT obaidullahahmadj developmentandvalidationofachiralliquidchromatographicassayforenantiomericseparationandquantificationofverapamilinratplasmastereoselectivepharmacokineticapplication AT altamimiabdulmaliks developmentandvalidationofachiralliquidchromatographicassayforenantiomericseparationandquantificationofverapamilinratplasmastereoselectivepharmacokineticapplication AT binjardanyousefa developmentandvalidationofachiralliquidchromatographicassayforenantiomericseparationandquantificationofverapamilinratplasmastereoselectivepharmacokineticapplication AT alhossainiabdullahm developmentandvalidationofachiralliquidchromatographicassayforenantiomericseparationandquantificationofverapamilinratplasmastereoselectivepharmacokineticapplication |